Silence Therapeutics is snatching back two siRNA drug targets developed through a $20 million collaboration with Mallinckrodt. The two companies agreed in 2019 to develop three siRNA drug targets that ...

(RTTNews) - Biotechnology company Q32 Bio, Inc. (QTTB) announced Monday it has sold its Phase 2 complement inhibitor, ADX-097, to Akebia Therapeutics, Inc. (AKBA). ADX-097, the lead product candidate ...

Akebia Therapeutics has struck a deal for Q32 Bio’s deprioritized complement inhibitor ADX-097, paying $7 million upfront for an asset that forms the centerpiece of its new rare kidney disease ...

In the last five years, neuronal pentraxins have emerged as potential markers of synaptic loss. In the case of NPTX2, researchers may now be able to explain why. In the March 29 Science Translational ...

Researchers identified several antibodies to the nucleocapsid protein from a convalescent COVID-19 patient. Tests found some can inhibit complement hyperactivation and could potentially lead to new ...

Q32 Bio (QTTB) announced that it has sold its Phase 2 complement inhibitor, ADX-097, to Akebia Therapeutics (AKBA). “This transaction strengthens our cash position through additional non-dilutive ...